イリノイ州における膠芽腫の臨床試験
イリノイ州内の拠点で、膠芽腫に関する16件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- University of Chicago Comprehensive Cancer Center, Chicago
- University of Chicago Medicine-Orland Park, Orland Park
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05432804Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Northwestern University, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05902169A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
- Northwestern Univerity, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05303467A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT05765812Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- Alton Memorial Hospital, Alton
- Decatur Memorial Hospital, Decatur
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/10更新 · NCT07452458Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
- Northwestern University, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06410248Targeted Pediatric High-Grade Glioma Therapy
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- Northwestern Medicine, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07464925WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Northwestern University, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05879250Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。